0acddbbc-6b74-4fdd-903d-f5ec9bfd8514
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 85.0869267624914
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.570
- MYC_TARGETS_V1+0.490
- DNA_REPAIR+0.470
- MYC_TARGETS_V2+0.470
- E2F_TARGETS+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- CHOLESTEROL_HOMEOSTASIS+0.330
- FATTY_ACID_METABOLISM+0.310
- PEROXISOME+0.310
- GLYCOLYSIS+0.270
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- UV_RESPONSE_DN-0.450
- HEDGEHOG_SIGNALING-0.400
- MITOTIC_SPINDLE-0.390
- ANGIOGENESIS-0.380
- INTERFERON_ALPHA_RESPONSE-0.350
- INTERFERON_GAMMA_RESPONSE-0.350
- APICAL_JUNCTION-0.330
- TGF_BETA_SIGNALING-0.300
- MYOGENESIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.926 |
| 2 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.919 |
| 3 | ERR2278847 | — | — | 0.894 |
| 4 | SRR975598 | — | — | 0.887 |
| 5 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.882 |
| 6 | ERR2278860 | — | — | 0.879 |
| 7 | TCGA-66-2766-01A-01R-0851-07 | — | cohortSQ2 | 0.877 |
| 8 | TCGA-CN-A6V7-01A-12R-A34R-07 | — | — | 0.875 |
| 9 | TCGA-37-4135-01A-01R-1100-07 | — | cohortA1 | 0.872 |
| 10 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.570 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.270 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |